Alan Forrest

Q: What Schools Are Affiliated With Alan Forrest

Alan Forrest is affiliated with the following schools: Monash University, University of Maryland, College Park, University at Buffalo, University of North Carolina at Chapel Hill

Alan Forrest's AcademicInfluence.com Rankings

Alan Forrest

Medical

#3422

World Rank

#3890

Historical Rank

Pharmacology

#429

World Rank

#482

Historical Rank

medical Degrees

Alan Forrest

Philosophy

#9792

World Rank

#13402

Historical Rank

Logic

#6749

World Rank

#8296

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Alan Forrest's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Alan Forrest Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan Forrest's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients (1993) (1114)
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia (2004) (874)
Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections (2004) (717)
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients (2011) (647)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. (2007) (636)
Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy (1998) (526)
Letter: Procaine and malignant hyperthermia. (1974) (421)
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing (2010) (373)
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. (2004) (352)
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. (2013) (324)
Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme (2003) (274)
Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia (2007) (231)
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. (1985) (201)
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. (2000) (188)
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. (2000) (164)
Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection (2007) (162)
Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model (2010) (155)
Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program (2003) (154)
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? (2016) (147)
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. (1997) (142)
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin (1993) (137)
Dosing Guidance for Intravenous Colistin in Critically Ill Patients (2016) (129)
Absolute oral bioavailability of ciprofloxacin (1986) (122)
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. (2007) (121)
Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model (2010) (119)
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? (2016) (117)
Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula (2011) (111)
Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2011) (111)
Vancomycin AUC24/MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during Hospitalization (2011) (103)
Factors Associated With Postoperative Infection (2001) (103)
Coadministration of Milk Thistle and Indinavir in Healthy Subjects (2003) (101)
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. (1991) (98)
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. (2016) (96)
The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2012) (92)
Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2013) (91)
Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection (2009) (89)
Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa (2008) (88)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model (2013) (87)
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. (2009) (85)
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. (2005) (85)
Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline (2011) (85)
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. (1987) (83)
Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin (2004) (83)
Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. (1998) (82)
Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid (2014) (81)
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. (2002) (80)
Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials (2003) (78)
The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. (1992) (77)
Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia (2009) (75)
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers (1985) (74)
Multiple-dose pharmacokinetics of imipenem-cilastatin (1984) (74)
Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates (2003) (73)
An evaluation of optimal sampling strategy and adaptive study design (1988) (72)
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. (2003) (71)
Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans (2006) (70)
A limited sampling strategy for cyclophosphamide pharmacokinetics. (1989) (69)
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function (1987) (69)
Dosing Guidance for Intravenous Colistin in Critically Ill Patients. (2016) (68)
Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling (2015) (68)
Use of adaptive control with feedback to individualize suramin dosing. (1992) (66)
Pharmacokinetics and Pharmacodynamics of Midazolam After Intranasal Administration (1997) (66)
Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance (2016) (65)
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. (2001) (64)
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs (1999) (64)
Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. (1999) (63)
Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane (2013) (62)
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. (1986) (60)
Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii (2017) (60)
Dose ranging study and constant infusion evaluation of ciprofloxacin (1986) (58)
A Gentamicin Pharmacokinetic Population Model and Once‐Daily Dosing Algorithm for Neonates (2003) (58)
Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area under the Inhibitory Curve is More Rapid for Ciprofloxacin Than for Cefmenoxime (1994) (56)
Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers (1998) (56)
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. (2013) (55)
Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens (2016) (54)
Normalization of hypertensive responses during ambulatory surgical stress by perioperative music. (2001) (54)
Pharmacodynamic interactions of antibiotics alone and in combination. (1998) (54)
Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi (2005) (54)
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors (2005) (54)
Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. (2015) (54)
Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients (2017) (54)
Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use (2015) (53)
Effect of dose size on bioavailability of ciprofloxacin (1987) (52)
Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype (2008) (50)
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm (2018) (50)
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. (2011) (50)
Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model (2015) (48)
Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events (2008) (48)
Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia (2009) (48)
AUIC — The Universal Parameter within the Constraint of a Reasonable Dosing Interval (1996) (47)
Erratum: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore (Clinical Infectious Diseases (2007) 44, (79-86)) (2007) (46)
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). (1989) (43)
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. (2007) (43)
Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition (2012) (42)
Pharmacokinetics and bioavailability of fluconazole in patients with AIDS (1993) (42)
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate (1989) (41)
Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. (2003) (41)
Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia (2010) (41)
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity (2017) (41)
Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations (2005) (41)
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. (2011) (40)
Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation: Selecting the Best Antimicrobial Dose to Treat an Infection (2010) (40)
Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants (1995) (40)
Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii (2016) (39)
Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model (2013) (39)
Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model (2017) (38)
Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. (2000) (38)
Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii (2016) (38)
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination (1986) (37)
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. (2002) (37)
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii (2017) (35)
Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia (2011) (35)
A prospective evaluation of optimal sampling theory in the determination of the steady‐state pharmacokinetics of piperacillin in febrile neutropenic cancer patients (1989) (34)
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. (2016) (34)
Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance (2012) (33)
A Prospective Evaluation of Propylene Glycol Clearance and Accumulation During Continuous-Infusion Lorazepam in Critically Ill Patients (2008) (33)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model (2016) (32)
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. (2008) (32)
Predictors of agr Dysfunction in Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates among Patients with MRSA Bloodstream Infections (2011) (32)
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. (2012) (32)
The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function (2006) (32)
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia (2013) (31)
New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease (2013) (31)
Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus (2012) (31)
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models (2016) (31)
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients (1987) (31)
Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. (2010) (30)
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia (2013) (30)
In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. (1997) (29)
Comparison of the Plasma, Urine and Blister Fluid Pharmacokinetics of Clarithromycin and Azithromycin in Normal Subjects (1997) (28)
Oral administration of fomepizole produces similar blood levels as identical intravenous dose (2008) (28)
Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients (2011) (27)
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. (1987) (27)
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. (2000) (26)
Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women (2012) (25)
Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies (2013) (25)
Weight-based heparin dosing: clinical response and resource utilization. (1998) (25)
Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks (2007) (24)
Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii (2015) (24)
Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. (2016) (24)
Sex‐Related Differences in the Pharmacokinetics of Oral Ciprofloxacin (2004) (24)
The Utility of Acute Physiology and Chronic Health Evaluation II Scores for Prediction of Mortality among Intensive Care Unit (ICU) and Non-ICU Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia (2012) (23)
Clinical Experience With Linezolid in Conjunction With Wound Coverage Techniques for Skin and Soft-Tissue Infections and Postoperative Osteomyelitis (2004) (22)
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers (1986) (22)
Evaluation of the Pharmacokinetics and Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies (2014) (22)
The Pharmacodynamics of Sumatriptan in Nitroglycerin‐Induced Headache (1999) (22)
Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study (2013) (21)
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. (2008) (20)
Prospective use of optimal sampling theory: Steady‐state ciprofloxacin pharmacokinetics in critically ill trauma patients (1989) (20)
Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections (2014) (19)
Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. (2013) (19)
Insulin use, adipokine profiles and breast cancer prognosis (2017) (19)
Effect of Aging on Atenolol Pharmacokinetics and Pharmacodynamics (1995) (19)
Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics (2013) (19)
Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects (2003) (19)
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population (2012) (18)
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. (2003) (18)
Controlled randomized group comparison of nomifensine and imipramine in depressive illness. (1977) (18)
Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime (1996) (18)
Using machine learning to optimise antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii. (2020) (17)
88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF) (2011) (17)
Effect of renal function on the bioavailability of ciprofloxacin (1990) (17)
Relationships between renal function and disposition of oral ciprofloxacin (1988) (17)
Assessment and modelling of antibacterial combination regimens. (2017) (16)
Ciprofloxacin pharmacokinetics in critically ill trauma patients. (1989) (16)
Pharmacokinetic modeling of recombinant interleukin‐2 in patients with human immunodeficiency virus infection (1998) (16)
Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers (1997) (16)
Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naive, Human Immunodeficiency Virus-Infected Subjects (2004) (16)
SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles (2005) (16)
Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. (2016) (15)
Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring (2007) (15)
Evaluation of a Sparse Sampling Strategy for Determining Vancomycin Pharmacokinetics in Preterm Neonates: Application of Optimal Sampling Theory (1997) (15)
Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae (2019) (14)
Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use. (2019) (14)
Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis. (2006) (14)
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. (2011) (14)
Modeling the response of pneumonia to antimicrobial therapy (1997) (13)
Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model (2007) (13)
Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats (2017) (13)
Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model (2017) (13)
Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals (2005) (13)
Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model (2017) (13)
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. (1991) (13)
Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (13)
Approaches to optimal dosing of hexamethylene bisacetamide (2004) (13)
Eprosartan Does Not Affect the Pharmacodynamics of Warfarin (1998) (13)
Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa (2018) (13)
Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia (2013) (13)
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. (2007) (12)
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. (2014) (12)
Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone. (2000) (12)
Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations. (1996) (12)
Absolute Bioavailability and Disposition of (−) and (+) 2′-Deoxy- 3′-Oxa-4′-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans (2000) (12)
Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients (1985) (12)
A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity (2013) (11)
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers (1987) (11)
Multiple-dose activate charcoal as adjunct therapy after chronic phenytoin intoxication. (1991) (11)
In Pursuit of the triple Crown: mechanism-based pharmacodynamic modeling for the optimization of 3-drug combinations against KPC-Producing Klebsiella pneumoniae. (2020) (11)
Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection (2001) (11)
Optimal Sampling Theory: Effect of Error in a Nominal Parameter Value on Bias and Precision of Parameter Estimation (1994) (11)
Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. (2003) (11)
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations (2016) (11)
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae (2017) (11)
Critical Need for Clarity in Polymyxin B Dosing (2017) (11)
Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis (1994) (10)
Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa (2019) (10)
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers (1984) (10)
Patterns of Prescribing ACE Inhibitors after Myocardial Infarction (1999) (10)
Effect of saturable clearance during high-dose mezlocillin therapy (1984) (10)
Effect of Concomitant Administration of Cimetidine Hydrochloride on the Pharmacokinetic and Safety Profile of Tamsulosin Hydrochloride 0.4 mg in Healthy Subjects (2002) (10)
Optimizing use of quinolones in the critically ill. (2007) (9)
Effects of the Concomitant Administration of Tamsulosin (0.8 mg/Day) on the Pharmacokinetic and Safety Profile of Theophylline (5 mg/kg): A Placebo-Controlled Evaluation (2002) (9)
Pharmacodynamic Variability beyond That Explained by MICs (2013) (9)
Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design (2015) (8)
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers (2008) (8)
Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics (2013) (8)
Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists. (2007) (8)
Effects of the concomitant administration of tamsulosin (0·8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects: a placebo‐controlled evaluation (2002) (8)
Relationship of Linezolid Minimum Inhibitory Concentration and Time to Bacterial Eradication in Treatment for Methicillin-Resistant Staphylococcus Aureus Infection (2008) (8)
Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need. (2006) (7)
Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers (2016) (7)
The Link Between Pharmacodynamics and Physiologically Based Pharmacokinetic Models (2013) (7)
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. (2006) (7)
Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy (2016) (7)
Clinical and Pharmacokinetic Studies on the New Platinum Complex Zeniplatin (CL286,558) (1991) (6)
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model. (2017) (6)
Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related Disorders (2011) (6)
Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model (2019) (5)
Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach (2016) (5)
Polymyxins for the treatment of lower respiratory tract infections; lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. (2021) (5)
Circulating adipokines data associated with insulin secretagogue use in breast cancer patients (2016) (5)
Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis. (2011) (5)
Relative Bioavailability of Orally Administered Fosphenytoin Sodium Injection Compared with Phenytoin Sodium Injection in Healthy Volunteers (2015) (5)
Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells (2015) (5)
The Population Pharmacokinetics of Amphotericin B Colloidal Dispersion in Patients Receiving Bone Marrow Transplants (1999) (5)
Statin treatment use in diabetic patients with breast cancer: A potential C-reactive protein mediated benefit. (2011) (5)
Vasoreactivity in Pre‐ and Postmenopausal Women: Evaluation by Pharmacodynamic Modeling (1998) (4)
TH1 and TH2 cytokines dataset in insulin users with diabetes mellitus and newly diagnosed breast cancer (2017) (4)
Population PKS & PDS of tamsulosin, in patients with benign prostatic hyperplasia (BPH) (1996) (4)
Cost Effectiveness of Cephalosporin Monotherapy and Aminoglycoside/Ureidopenicillin Combination Therapy (2012) (4)
Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen) (1985) (4)
Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes (2018) (4)
Correspondence re: M. J. Egorin et al. Pharmacokinetics and Dosage Reduction of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum in Patients with Impaired Renal Function. Cancer Res., 44: 5432–5438, 1984—Reply (1987) (4)
p16INK4a, a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV‐Infected Subjects (2016) (4)
Pharmacodynamic Interactions of Ciprofloxacin, Piperacillin, and Piperacillin/Tazobactam in Healthy Volunteers (1998) (4)
Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables (2006) (4)
AMGET, an R-Based Postprocessing Tool for ADAPT 5 (2013) (4)
Advances in pharmacogenomics of antiretrovirals: an update. (2007) (3)
Predicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment (2019) (3)
Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression (2016) (3)
Population Pharmacokinetics of CEM-102 in Healthy Subjects (2009) (3)
Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males (2000) (3)
Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer (2017) (3)
Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine (2017) (3)
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients (2021) (3)
Compartmental analysis of saquinavir (SQV) pharmacokinetics (PK) (2005) (2)
Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer (2017) (2)
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analysis for Solithromycin to Support Intravenous Dose Selection in Patients with Community-Acquired Bacterial Pneumonia (2012) (2)
Reply to Pai. (2013) (2)
Definition and Validation of a Novel Metric of Erythropoiesis‐Stimulating Agent Response in Hemodialysis Patients (2019) (2)
Polymyxin Combinations against Pseudomonas aeruginosa : Profiling the Time-Course of Synergistic Killing and Prevention of Resistance (2015) (2)
Predictors of Trough Concentrations of Oral Ciprofloxacin (1993) (2)
Population Pharmacokinetics of Solithromycin (CEM-101) Using Data from the Plasma and Epithelial Lining Fluid of Healthy Subjects (1986) (2)
Reply to Corona and Cattaneo. (2017) (2)
Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer (2017) (2)
High-dose olanzapine for bipolar depression: proceed with caution. (2014) (2)
Dataset on growth factor levels and insulin use in patients with diabetes mellitus and incident breast cancer (2017) (2)
Insulin use, hormone receptor status and hematopoietic cytokines׳ circulation in women with diabetes mellitus and breast cancer (2017) (2)
PK/PD of pegylated‐liposomal doxorubicin (LD) and the appearance of dermal lesions in dogs (1996) (2)
Translational Modeling of Antibacterial Agents (2016) (2)
CEM-102 (Sodium Fusidate) Dosage Regimen Decision Support Using Population Pharmacokinetic (PPK) and Mechanism- Based Pharmacokinetic-Pharmacodynamic (PK-PD) Models (2009) (2)
Safety and tolerability of multiple doses of imipenem/cilastatin (1985) (2)
Steady-State SerumPharmacokinetics ofNovobiocin andRifampin Alone andinCombination (1986) (2)
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients (2020) (1)
A new model for bacterial growth & drug effects (1999) (1)
Modeling of Toxicities Due to Antibiotics (2007) (1)
Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients (2017) (1)
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs (2004) (1)
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors (2022) (1)
BETA BLOCKERS IN THE· ELDERLY (1986) (1)
Delafloxacin Population Pharmacokinetics and Covariate Exploration (2010) (1)
Population Pharmacokinetics (PPK) of Plazomicin and Use of Therapeutic Drug Management (TDM) in Critically Ill Patients (2016) (1)
Pharmacodynamic interactions of ciprofloxacin , piperacillin , and piperacillin/tazobactam in volunteer subjects (1994) (1)
Development ofa Population Pharmacokinetic Modeland Optimal Sampling Strategies forIntravenous Ciprofloxacin (1993) (1)
Prophylaxis and in Patients With Recurrent Ischemic Events Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke (2008) (1)
Effect of Food on the Pharmacokinetics of (‐) and (+) dOTC When Administered as an Oral Racemate (2002) (1)
TH1 and TH2 cytokine data in insulin secretagogues users newly diagnosed with breast cancer (2017) (1)
F021: Assessment of current treatment trends in the management of high risk hypertension (2000) (0)
398Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures (2014) (0)
Daunorubicin (DNR) plasma pharmacokinetics (PKs) and pharmacodynamics (PDs) (1990) (0)
Co-modelling of daunorubicin and daunorubicinol pharmacokinetics (1990) (0)
Phase I Clinical and Pharmacokinetic Study of Hexamethylene Bisacetamide (NSC 95580) Administered as a Five-Day Continuous Infusion1 (2006) (0)
Application of SPLINDID, a Semiparametric, Model-Based Method for Pharmacogenomic Modeling of mRNA Dynamics (2006) (0)
487Infections Caused by Enterobacteriaceae Species following Cardiac Surgery: Impact of Polymyxin Resistance on Treatment Outcomes (2014) (0)
Analysis of cardiovascular drugs as predictors of hospital readmission in heart failure (HF) patients (1996) (0)
Multiple dose pharmacokinetics pks of po opc 17116 in normal subjects 400 vs 800 mg parallel design (1992) (0)
48* Nebulized SLIT™ Amikacin in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection in Serbia and Hungary (2007) (0)
Changes in coronary sinus and femoral artery blood concentrations of K+, Na+ and Ca2+ following cardiopulmonary bypass surgery (1987) (0)
Characterization of the Pharmacokinetics-Pharmacodynamics of Tazobactam in 1 Combination with Piperacillin in an In Vitro Infection Model 2 (2016) (0)
Pharmacokinetics of Nelﬁnavir and Efavirenz in Antiretroviral-Naı¨ve, Human Immunodeﬁciency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (0)
Optimal sparse pharmacokinetic (PK) sampling strategies (OSS) for multi‐drug antiretroviral (ARV) regimens (2005) (0)
Optimal multi‐drug PK sampling strategies (OSS) for efavirenz (EFV) & indinavir (IDV) (2005) (0)
Pharmacometric modelling of risk factors for MRSA (1997) (0)
A pharmacometric model for factors in the development of bacterial resistance in acutely ill patients (1997) (0)
Effect ofRenalFunction on theBioavailability ofCiprofloxacin (1990) (0)
Ciprofloxacin Eradicates Respiratory Tract Bacteria More Rapidly than Cephalosporins in Patients with Nosocomial Pneumonia (1993) (0)
Pharmacokinetics andBioavailability ofFluconazole in Patients withAIDS (1993) (0)
Plasmacidal activity (PCA) in plasma of acute myelocytic leukemia (AML) patients (pts) receiving daunorubicin (DNR) (1989) (0)
Use of Pharmacokinetics-Pharmacodynamics and Monte Carlo Simulation Analyses to Support Brilacidin Dose Selection for Patients with Acute Bacterial Skin and Skin Structure Infections (2013) (0)
Ciprofloxacin Breakpoints in Enteric Fever: Time to Revise our Susceptibility criteria (2009) (0)
Pharmacology Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model B (2006) (0)
Co-modelling of daunorubicin (D1) and daunorubicinol (D2) plasma pharmacokinetics (PKs) and pharmacodynamics (PDs) (1990) (0)
Pharmacokinetics ofIntravenously Administered Ciprofloxacin in Patients withVarious Degrees ofRenalFunction (1987) (0)
Standard (S2S) versus iterative-2 (IT2S) stage population analysis of daunorubicin (D1) and daunorubicinol (D2) pharmacokinetics (1991) (0)
Abstract LB-329: Use of insulin sensitizers is associated with better hormone-receptor pattern and improved breast cancer outcomes (2012) (0)
NOTES Steady-State Pharmacokinetics ofImipenem inFebrile Neutropenic Cancer Patients (1987) (0)
Pharmacodynamics (PD) of sumatriptan (S) in nitroglycerin-(NTG) induced headache (HA) (1997) (0)
Pharmacokinetics-Pharmacodynamics of Gatiﬂoxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model (cid:1) (2007) (0)
Materials and Methods Pharmacokinetics-Pharmacodynamics of CEM-102 (Sodium Fusidate) Against Streptococcus pyogenes Using In Vitro Pharmacodynamic Models (2009) (0)
Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition (2012) (0)
Correspondence Failure of Vancomycin for Treatment of Methicillin- Resistant Staphylococcus aureus Infections (2004) (0)
Absolute OralBioavailability ofCiprofloxacin (1986) (0)
Comparison of in vivo uptake of azithromycin (A) vs. clarithromycin (C) into polymorphonuclear leukocytes (PMNS) (1997) (0)
PK-PD Evaluation of Daptomycin (DAP) Against S. aureus (SA) Strains with Increased MIC Values after DAP Exposure (2008) (0)
Gastrostomy complications in childhood (2001) (0)
Abstract LB-421: Diabetes pharmacotherapy: A potential modifier of breast cancer prognosis: Table 1. (2010) (0)
Relationships between serum, intracellular, and infection site concentrations of macrolide and azalide antibiotics: A theoretical exploration of the concept of white blood cell drug delivery to infection sites (1996) (0)
Effect ofDoseSize on Bioavailability ofCiprofloxacin (1987) (0)
PIII‐35 (2006) (0)
POPULATION PHARMACOKINETIC (PK) MODEL OF MYCOPHENOLIC ACID (MPA) AND ITS METABOLITE— MYCOPHENOLIC ACID GLUCORONIDE (MPAG) IN LONG TERM TRANSPLANT RENAL PATIENTS USING MONTE- CARLO PARAMETRIC EXPECTATION MAXIMIZATION (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alan Forrest?

Alan Forrest is affiliated with the following schools:

Alan Forrest's Academic­Influence.com Rankings

Alan Forrest's Degrees

Why Is Alan Forrest Influential?

Alan Forrest's Published Works

Published Works

What Schools Are Affiliated With Alan Forrest?

Alan Forrest's AcademicInfluence.com Rankings